当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Novel procedure of treating sub-macular haemorrhage (SMH) with only pneumatic displacement (PD)

Dr Gitumoni Sharma

Sub macular haemorrhage results from Choroidal and retinal vessel abnormalities. Sub macular haemorrhage frequently results from a Choroidal neovascular membrane secondary to age-related macular degeneration. Other conditions related to CNVM, including myopia, trauma, ocular histoplasmosis and angioid streaks, also can cause sub macular hemorrhage.1-3 little , thin SMH can often be observed (See Figure 1), while massive submacular haemorrhages often have a poor prognosis no matter intervention.1 Thick, medium-sized subretinal hemorrhages that reach under the macula and obscure the underlying retinal pigment epithelium can also cause significant vision loss; however, they are often amenable to treatment. There are a variety of treatments targeted at the removal or displacement of the hemorrhage. Some techniques are office-based, while others are performed in the operating room. Pneumatic displacement of SMH (with and without tissue plasminogen activator [t-PA]) is an office-based procedure first described by Wilson J. Heriot, MD, in 1996 and has shown some success in subsequent small case series.5-8 This technique attempts to physically displace the SMH out of the fovea using expansile gas.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。